0OT Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsConsistently high gross margins indicate that the company’s ophthalmic products can retain substantial value after direct costs. If revenue scales, this margin profile could support improved operating leverage and provide a durable foundation for future profitability once development and commercial expenses moderate.
Manageable LeverageImproved leverage and assets that are sizable relative to debt provide financial flexibility compared with a highly leveraged biotech. This may give Ocular Therapeutix more room to fund development, manage volatility, and pursue commercialization while reducing balance-sheet pressure.
Specialized Drug-Delivery PlatformA focused bioresorbable hydrogel platform gives Ocular Therapeutix a specialized foundation for developing sustained-release ophthalmic treatments. Improving dosing convenience and clinical outcomes can support differentiated products and a repeatable development strategy across eye-disease indications.
Bears Say
Persistent Operating LossesLarge and worsening operating losses show that strong gross margins have not yet translated into sustainable earnings. Continued losses can constrain internal investment capacity and leave future financial performance dependent on successful commercialization or additional funding.
Heavy Cash BurnPersistent negative operating and free cash flow means the business is not yet self-funding. If the higher TTM burn continues, Ocular Therapeutix may face recurring funding needs, which could limit strategic flexibility and increase pressure to obtain capital.
Weak Revenue TrendA material annual revenue decline followed by only modest TTM growth indicates limited top-line momentum. Without stronger and more consistent revenue expansion, fixed development and commercial costs are harder to absorb, delaying the path toward operating profitability.
Ocular Therapeutix News
0OT FAQ
What was Ocular Therapeutix’s price range in the past 12 months?
Currently, no data Available
What is Ocular Therapeutix’s market cap?
Ocular Therapeutix’s market cap is CHF1.37B.
When is Ocular Therapeutix’s upcoming earnings report date?
Ocular Therapeutix’s upcoming earnings report date is Nov 09, 2026 which is in 30 days.
How were Ocular Therapeutix’s earnings last quarter?
Ocular Therapeutix released its earnings results on Aug 03, 2026. The company reported -CHF0.291 earnings per share for the quarter, beating the consensus estimate of -CHF0.328 by CHF0.037.
Is Ocular Therapeutix overvalued?
According to Wall Street analysts Ocular Therapeutix’s price is currently Undervalued.
Does Ocular Therapeutix pay dividends?
Ocular Therapeutix does not currently pay dividends.
What is Ocular Therapeutix’s EPS estimate?
Ocular Therapeutix’s EPS estimate is -0.3.
How many shares outstanding does Ocular Therapeutix have?
Ocular Therapeutix has 219,615,880 shares outstanding.
What happened to Ocular Therapeutix’s price movement after its last earnings report?
Ocular Therapeutix reported an EPS of -CHF0.291 in its last earnings report, beating expectations of -CHF0.328. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Ocular Therapeutix?
Currently, no hedge funds are holding shares in CH:0OT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocular Therapeutix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF21.23 (― Upside)
CHF21.23 (― Upside)
Blogger Sentiment
Bullish
CH:0OT Sentiment 64%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth CHF210.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.94%
12-Months-Change
Fundamentals
Return on Equity
-59.87%
Trailing 12-Months
Asset Growth
48.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
0OT Stock 12 Month Forecast
Average Price Target
―EyePoint Pharmaceuticals
―
RegenXBio
―
Tarsus Pharmaceuticals
―
Oculis Holding
―
Aura Biosciences Inc
―